$SKYE News
Last published 1d ago
- 1d agoSKYETrading halt: Skye Bioscience, Inc. CS (SKYE), Volatility trading pauseNasdaq Trading HaltsHalted 2026-11-10 09:39:20.606 ET, resumption quote 2026-11-10 09:39:20 ET, resumption trade none.
- 2mo agoSKYESkye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in FinancingsGlobeNewswireCombined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and boardCompany’s lead program will be RXC008, Redx’s GI-restricted pan-ROCK inhibitor
- 5mo agoSKYESkye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1GlobeNewswireSAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders,
- 6mo agoSKYEUPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateGlobeNewswireCBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2 SAN DIEGO, May 12, 2026 (GLOBE
- 6mo agoSKYESkye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateGlobeNewswireCBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2Engaged Lilly Catalyze360 to provide
- 6mo agoSKYEKuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law FirmGlobeNewswireNEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ:SKYE) breached their fiduciary
- 7mo agoSKYESkye Bioscience Presenting at GLP-1-Based Therapeutics SummitGlobeNewswireSAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye") a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health
- 7mo agoSKYESkye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination DevelopmentGlobeNewswireSAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye") a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health
- 8mo agoSKYESkye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireInitiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV cohorts;Received written FDA Type C meeting minutes; feedback is
- 8mo agoSKYESkye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026GlobeNewswireSAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health
- 9mo agoSKYESkye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With SemaglutideGlobeNewswire22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab dosesWeight
- 9mo agoSKYESkye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity ConferenceGlobeNewswireSAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye") a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health
- 9mo agoSKYESkye Bioscience to Present Poster at Keystone Obesity ConferenceGlobeNewswireSAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye") a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health
- 9mo agoSKYEKuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law FirmGlobeNewswireNEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ:SKYE) breached their fiduciary
- 10mo agoSKYEINVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye BioscienceGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 10mo agoSKYESkye Provides 2026 Corporate OutlookGlobeNewswireCBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring Committee (DMC) meeting on December 14, 2025, continued to demonstrate favorable safety
- 10mo agoSKYESKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye BioscienceGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 10mo agoSKYEKuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ: SKYE)...
- 10mo agoSKYEINVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye BiosciencePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. ("Skye" or the...
- 10mo agoHALOSKYEHalozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for ObesityGlobeNewswireSAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Skye Bioscience, Inc. (NASDAQ:SKYE) today announced the companies entered into a non-exclusive global collaboration and license
- 10mo agoHALOSKYEHalozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for ObesityPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global ...
- 10mo agoSKYEUPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye BioscienceGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 10mo agoSKYEDid You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.Business WireRobbins LLP: Company: Skye Bioscience, Inc. (NYSE:SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors ("GPCRs") to treat obesity,
- 11mo agoSKYEINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye BiosciencePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. ("Skye" or the...
- 11mo agoSKYEShareholders of Skye Bioscience, Inc. Should Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights - SKYEPR NewswireThe Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE...
- 11mo agoSKYESKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye BioscienceGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 11mo agoSKYESkye Bioscience, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SKYEPR NewswireThe Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE...
- 11mo agoSKYEUPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye BiosciencePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Bioscience, Inc. ("Skye" or the...
- 11mo agoSKYESKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye BioscienceGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 1y agoSKYESkye Bioscience Reports Third Quarter 2025 Financial Results and Business UpdateGlobeNewswireTopline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide alone after 26 weeks of treatment; the data demonstrated a clean
- 1y agoSKYESkye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight GainGlobeNewswireSAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health
- 1y agoSKYESkye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025GlobeNewswireSAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health
- 1y agoCNTXSKYEStep Pharma announces the appointment of Dr Karen Smith as Chief Medical OfficerGlobeNewswireKaren Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's
- 1y agoSKYESkye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical TrialGlobeNewswireNimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a
- 1y agoSKYESkye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual MeetingGlobeNewswireSAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health
- 1y agoSKYESkye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoSKYESkye Bioscience, Inc. (SKYE) Virtual KOL Event TranscriptEarnings Call Transcripts
- 1y agoSKYESkye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO ModelGlobeNewswireSkye shares new preclinical DIO data at virtual KOL eventNimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment weight loss compared to
- 1y agoSKYESkye Completes 26-week Treatment Phase in Phase 2a CBeyond™ StudyGlobeNewswireSAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health
- 1y agoSKYESkye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data ReadoutGlobeNewswireSAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health
- 1y agoSKYESkye Bioscience to Participate in Upcoming Investment and Medical ConferencesGlobeNewswireSAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health
- 1y agoSKYESkye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoSKYESkye Bioscience Reports Second Quarter 2025 Financial Results and Business UpdateGlobeNewswireReiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in Skye's CBeyondTM Phase 2a obesity trial extension study initiated Independent Data
- 1y agoSKYESkye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025GlobeNewswireSAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health
- 1y agoSKYESkye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific SessionsGlobeNewswireSAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health
- 1y agoSKYESkye Bioscience to Participate in Upcoming Investment ConferencesGlobeNewswireSAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health
- 1y agoSKYESkye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate NimacimabGlobeNewswireSAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health
- 1y agoSKYESkye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced
- 1y agoSKYESkye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on ObesityGlobeNewswire• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small
- 1y agoSKYESkye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in ObesityGlobeNewswireNimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity modelIn vitro data